Already have an account? Sign In
VectorBuilder, founded in 2014 and headquartered in Guangzhou, China, is a biotechnology company specializing in gene delivery solutions. The company offers a wide range of services, including vector construction, plasmid DNA preparation, virus packaging, and gene delivery solutions. VectorBuilder also provides services for CRISPR/shRNA library construction, stable cell line development, mRNA in vitro transcription, and recombinant protein expression purification.
Since its inception, VectorBuilder has shown significant growth and attracted investor interest. The company has successfully completed multiple funding rounds, including a Series C round in October 2022 that raised $57.3 million and valued the company at $1 billion. This funding round was led by notable investors such as Legend Capital, Guangzhou Small and Medium Enterprise Development Fund, and Yuexiu Industrial Fund. VectorBuilder's most recent funding event was a Series C-II round in March 2023, further demonstrating continued investor confidence in the company's potential.
While there is currently no official news or confirmed information regarding VectorBuilder's IPO prospects, the company's strong funding history and valuation suggest it may be positioning itself for future growth opportunities. However, it's important to note that many factors can influence a company's decision to go public, including market conditions, regulatory environment, and internal strategic goals.
Investors interested in the biotechnology sector and potential investment opportunities in companies like VectorBuilder should continue to monitor official announcements and verified news sources for any updates on the company's plans. As always, it's crucial to conduct thorough research and consider various factors before making any investment decisions.
Already have an account? Sign In
While VectorBuilder's IPO prospects remain uncertain, investors interested in the biotechnology and gene delivery sector don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides opportunities to invest in potential industry leaders like VectorBuilder, with lower minimum investments than traditional private equity options. This allows you to diversify your portfolio and potentially benefit from the growth of innovative companies in the biotech space.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.